Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Investigators estimate 40-50% of proton pump inhibitor users are using inappropriately.
Muhammad Ali Khan, MD
The long-term use of proton pump inhibitors is linked to a number of potentially serious adverse events, such as an increased risk of dementia. However, studies showing this link have been conflicting in the past.
A team in the US and Canada, led by Muhammad Ali Khan, MD, Division of Gastroenterology and Hepatology, University of Alabama, evaluated the association between the long-term use of proton pump inhibitors and an increased risk of dementia.
Overall, 11 studies met their criteria, involving 642,949 patients. The majority of studies ranged from 5-10 years.
There were a total of 158,954 PPI users to go along with 483,995 non-users.
The investigators examined various databases for studies examining the link between PPI use and dementia, up to February 2019. They then pooled the studies using the DerSimonian and Laird random effects model for meta-analyses and assessed the quality of individual observational studies using the Newcastle-Ottawa scale.
Using this scale, the investigators found 10 studies of high quality and 1 study that was deemed moderate quality.
Finally, the team assessed the overall quality of evidence using the GRADE approach. And found the quality of evidence for both outcomes was very low.
For the studies summarizing data as adjusted hazard ratios (HR), the pooled HR for all causes of dementia was 1.10 (95% CI, 0.88-1.37). For only Alzheimer dementia, the pooled HR was 1.06 (95% CI, 0.72-1.55).
For the studies summarizing data as adjusted odds ratio (OR), the pooled OR for all causes of dementia was 1.03 (95% CI, 0.84-1.25) and 0.96 (95% CI, 0.82-1.11) for Alzheimer dementia only.
Recently, a research team, led by Sean D. Delshad, MD, Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), performed a population-based study to determine the prevalence of gastroesophageal reflux disease (GERD) symptoms and persistent GERD symptoms despite the use of PPIs and found half of PPI users still have persistent symptoms.
The study included 71,812 participants, with 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported having GERD symptoms in the last week.
They found certain trends along demographical lines, where younger individuals, women, Latinos, and participants with irritable bowel syndrome or Crohn’s disease were more likely to have continued symptoms, even when taking PPIs.
The investigators suggest further studies are needed to develop new therapies for patients with PPI-refractory GERD symptoms.
Proton pump inhibitors are essential for the management of acid-related upper gastrointestinal disorders. Approximately 20% of older adults take PPIs, the majority of which do so on a long-term basis.
However, the authors believe proton pump inhibitors could be used inappropriate in up to 40-50% of patients and have been overprescribed in a variety of healthcare settings including outpatient clinics, nursing homes, and rehabilitation centers.
While there is some concern over PPI use in these settings, there is no current connection between the treatment and the risk of developing dementia.
“We found no evidence to support the proposed association between PPI use and an increased risk of dementia,” the authors wrote. “PPI use among patients who have a valid indication for it, should not be curtailed because of concerns about dementia risk.”
The study, “No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia,” was published online in The American Journal of Gastroenterology.